FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
Hosted on MSN13d
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
Type 2 diabetes (T2D) patients with CKD will be eligible for the approval. The new indication makes Ozempic the first ...
This is Money7d
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...
Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.